{"id":"2wipv-1sipv","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability or fussiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The 2wIPV+1sIPV schedule represents a mixed vaccination strategy combining whole-virus inactivated polio vaccine (wIPV) with split-virus inactivated polio vaccine (sIPV). The whole-virus component provides robust immunogenicity, while the split-virus component may offer improved safety profile. This heterologous prime-boost approach aims to optimize both immune response and tolerability in polio prevention.","oneSentence":"This is a combination inactivated polio vaccine regimen using two doses of whole-virus IPV followed by one dose of split-virus IPV to provide immunization against poliovirus types 1, 2, and 3.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:25:25.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention (poliovirus types 1, 2, and 3)"}]},"trialDetails":[{"nctId":"NCT07457060","phase":"PHASE4","title":"Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-11-27","conditions":"Poliomyelitis","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"2wIPV+1sIPV","genericName":"2wIPV+1sIPV","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Researchers conducted a Phase IV clinical study (NCT07457060) to evaluate the immunogenicity and safety of a sequential vaccination regimen using 2 doses of wild-type inactivated poliovirus vaccine (2wIPV) plus 1 dose of Sabin-type inactivated poliovirus vaccine (1sIPV) in individuals with poliomyelitis. This study compared the immunogenicity of this regimen to other vaccination schedules, including 1wIPV+2sIPV and 3wIPV.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}